Phase 3 Readout~month

Phase 3 Topline: A Phase III Randomized Trial of Eribulin (NSC #707389) With Gemcitabine Versus Standard of Care (Phy

Indication
Metastatic Bladder Urothelial Carcinoma; Stage IV Bladder Cancer AJCC v8; Metastatic Urothelial Carcinoma

Other upcoming events for ABUS

Patent ExpiryPatent/Exclusivity Expiry: HALAVEN
Patent ExpiryPatent/Exclusivity Expiry: VEMLIDY

Track this catalyst and more

Get real-time alerts, AI-powered analysis, and full catalyst coverage.

Start FreeFull Calendar
    Phase 3 Topline: A Phase III Randomized Trial of Eribulin (NSC #707389) With Gemcitabine Versus Standard of Care (Phy — ABUS Phase 3 Readout | BioSniper